Artificial, Inc. Announces Promotion of Nikhita Singh to Chief Product Officer
Artificial, a lab automation company that is catalyzing the life science digital revolution with its first-of-its-kind orchestration platform, announced that Nikhita Singh has been promoted to the role of Chief Product Officer (CPO). Joining Artificial in 2018, Nikhita is one of the founding team members at Artificial and brings with her over 10 years’ experience as a product strategist, designer, and technologist at institutions such as MIT Media Lab and companies like Palantir.
Recommended AI News: G2 recognizes RFP360 as Best Software for 2021
As CPO, Nikhita will spearhead Artificial’s product strategy and development to ensure that their software platform will lower the barrier of adoption of robotics and automation so labs can accelerate their next breakthrough. Before Artificial, Nikhita was a researcher at the Personal Robots Group at the MIT Media Lab where she designed and studied socially intelligent robots and AI platforms. Nikhita also drove product at Palantir for several Fortune 500 companies and government agencies in the US and Europe. She received her M.S. in Media Arts & Science from the Massachusetts Institute of Technology and her B.S. in Industrial Engineering and Operations Research from the University of California-Berkeley.
Recommended AI News: Quantiphi Named as an IDC Innovator in Artificial Intelligence Services
“Nikhita’s appointment to CPO reflects her deep understanding of robotics, AI, and human-centered design. She brings a fresh perspective to how humans and automation systems can interact in the lab for maximally efficient and reliable operations,” says David Fuller, CEO of Artificial. “I am confident that under Nikhita’s leadership, we will continue to advance aLab Suite’s development at a rapid pace and address the urgent needs of the life science market. Nikhita has already made significant contributions to Artificial’s growth and product and I look forward to continuing to work together as we catalyze the life science’s digital revolution.”
“I look forward to continuing to work with our teams to build out a first-of-its-kind automation platform for the life sciences,” says Nikhita. “The scientific process is a combination of art and science. It enables discoveries and innovations like gene editing, as well as enables scientists to be creative as they develop new approaches to society’s biggest problems like COVID-19 diagnostics. While this combination of art and science makes its modernization difficult, I look forward to driving the development of a solution that empowers all labs to quickly and reliably adopt and scale their automation in support of their next breakthrough.”
Recommended AI News: IP Infusion Selected by EvoNet as Key Partner for Future Network Expansion